Unapproved retatrutide products cause severe health risks in Australia

Consensus Summary

A patient in Australia suffered a life-threatening torn oesophagus after using a counterfeit product falsely labelled as retatrutide, an unapproved weight-loss peptide. The Therapeutic Goods Administration (TGA) confirmed the product contained no retatrutide but instead had semaglutide at levels eight times higher than those in approved semaglutide medications. The patient experienced uncontrollable vomiting, leading to the severe injury and hospitalisation. Both ABC and The Guardian report that the TGA has issued urgent warnings about the dangers of unapproved peptides, which are widely promoted online despite lacking regulatory approval or safety testing.

Retatrutide, currently undergoing clinical trials, is not authorised for sale or prescription in Australia. The TGA has repeatedly cautioned that these products may contain unknown substances, incorrect dosages, or contaminants, posing serious health risks. The Guardian notes that the Victorian health department issued a warning in June about six cases of acute liver toxicity linked to products labelled as retatrutide, further highlighting the dangers of unregulated use. The ABC reports that the TGA’s testing revealed the counterfeit product contained undeclared semaglutide, a drug used in approved weight-loss medications like Ozempic and Wegovy.

Key figures in the response include TGA’s chief medical adviser, Prof. Robyn Langham, who emphasised the risks of unapproved injectable peptides, including infection and allergic reactions. The Guardian quotes Langham warning that users face dangers from unknown contents, non-sterile manufacturing, and incorrect dosing. ABC highlights Dr. Darcy Holt, a Melbourne gastroenterologist, who described the torn oesophagus as a medical emergency and noted that high doses of these drugs can cause extreme nausea and vomiting, leading to such injuries. Both outlets stress that these products are being sold illegally on the black market under various names, including Reta, R-10, and R-20.

While both sources agree on the core facts, the Guardian provides specific details about the Victorian health department’s June warning regarding liver toxicity cases, whereas ABC focuses on the recent surge in unapproved peptide use over the past three to six months. The Guardian also notes that the TGA obtained a sample confirming the high semaglutide levels, while ABC includes additional context from a partnership with the University of Queensland that tested black-market vials. Neither source contradicts the other on key figures, but their emphasis differs slightly, with ABC placing more weight on the recent spike in usage and ABC’s partnership testing.

The TGA has made it clear that unapproved peptides should not be used outside clinical trials, and both outlets warn of the potential for severe adverse effects, including liver damage, inflammation, and allergic reactions. The Guardian and ABC both stress that these products are not subject to the same quality controls as approved medications, increasing the risk of contamination or incorrect dosing. While the immediate focus is on the patient’s injury and the TGA’s warnings, the long-term concern remains the proliferation of these dangerous substances on the black market, with no clear resolution in sight beyond continued regulatory alerts.